Dansranjavin T, Wagenlehner F, Gattenloehner S, Steger K, Weidner W, Dammann R, Schagdarsurengin U (October 2012). "Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma". The Prostate. 72 (14): 1550–8. doi:10.1002/pros.22510. PMID22415519.
Hill VK, Underhill-Day N, Krex D, Robel K, Sangan CB, Summersgill HR, Morris M, Gentle D, Chalmers AD, Maher ER, Latif F (February 2011). "Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis". Oncogene. 30 (8): 978–89. doi:10.1038/onc.2010.471. PMID20956940.
Helmbold P, Richter AM, Walesch S, Skorokhod A, Marsch WC, Enk A, Dammann RH (March 2012). "RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi". The Journal of Investigative Dermatology. 132 (3 Pt 1): 687–94. doi:10.1038/jid.2011.380. PMID22113481.
Li X, Liang Q, Liu W, Zhang N, Xu L, Zhang X, Zhang J, Sung JJ, Yu J (May 2016). "Ras association domain family member 10 suppresses gastric cancer growth by cooperating with GSTP1 to regulate JNK/c-Jun/AP-1 pathway". Oncogene. 35 (19): 2453–64. doi:10.1038/onc.2015.300. PMID26279301.
Li Z, Chang X, Dai D, Deng P, Sun Q (April 2014). "RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer". Oncology Reports. 31 (4): 1661–8. doi:10.3892/or.2014.3039. PMID24573726.
Lu D, Ma J, Zhan Q, Li Y, Qin J, Guo M (April 2014). "Epigenetic silencing of RASSF10 promotes tumor growth in esophageal squamous cell carcinoma". Discovery Medicine. 17 (94): 169–78. PMID24759621.
Schagdarsurengin U, Richter AM, Wöhler C, Dammann RH (November 2009). "Frequent epigenetic inactivation of RASSF10 in thyroid cancer". Epigenetics. 4 (8): 571–6. PMID19934646.
Wei Z, Chen X, Chen J, Wang W, Xu X, Cai Q (March 2013). "RASSF10 is epigenetically silenced and functions as a tumor suppressor in gastric cancer". Biochemical and Biophysical Research Communications. 432 (4): 632–7. doi:10.1016/j.bbrc.2013.02.033. PMID23428420.